1887
Research article Open Access
Like 0

Abstract

We conducted a multicentre test-negative case–control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2017.22.30.30580
2017-07-27
2017-11-24
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2017.22.30.30580
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/22/30/eurosurv-22-30-2.html?itemId=/content/10.2807/1560-7917.ES.2017.22.30.30580&mimeType=html&fmt=ahah

References

  1. Mertz D, Kim TH, Johnstone J, Lam P-P, Science M, Kuster SP, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ. 2013;347(aug23 1):f5061.
  2. Hewitt R, Farne H, Ritchie A, Luke E, Johnston SL, Mallia P. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis. 2016;10(2):158-74.  https://doi.org/10.1177/1753465815618113  PMID: 26611907 
  3. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med. 2008;121(4):258-64.  https://doi.org/10.1016/j.amjmed.2007.10.040  PMID: 18374680 
  4. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9(8):493-504.  https://doi.org/10.1016/S1473-3099(09)70175-6  PMID: 19628174 
  5. Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41(3):281-8.  https://doi.org/10.1086/431587  PMID: 16007521 
  6. Frasca D, Diaz A, Romero M, Mendez NV, Landin AM, Ryan JG, et al. Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine. Vaccine. 2013;31(35):3603-10.  https://doi.org/10.1016/j.vaccine.2013.05.003  PMID: 23711934 
  7. Muszkat M, Friedman G, Dannenberg HD, Greenbaum E, Lipo M, Heymann Y, et al. Response to influenza vaccination in community and in nursing home residing elderly: relation to clinical factors. Exp Gerontol. 2003;38(10):1199-203.  https://doi.org/10.1016/j.exger.2003.07.004  PMID: 14580873 
  8. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010; (2):CD004876. PMID: 20166072 
  9. Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev. 2013; (10):CD008983. PMID: 24166741 
  10. Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis. BMC Med. 2015;13(1):53.  https://doi.org/10.1186/s12916-015-0295-6  PMID: 25857236 
  11. Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev. 2013; (2):CD000364. PMID: 23450529 
  12. Poole PJ, Chacko E, Wood-Baker RWB, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006; (1):CD002733. PMID: 16437444 
  13. Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015; (5):CD005050. PMID: 25940444 
  14. Council of the European Union. Council recommendation of 22 December 2009 on seasonal influenza vaccination. Official Journal of the European Union. Luxembourg: Publications Office of the European Union; 2009. http://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32009H1019&from=EN
  15. Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec. 2012;87(47):461-76. PMID: 23210147 
  16. European Centre for Disease Prevention and Control (ECDC). Seasonal influenza vaccination in Europe - Overview of vaccination recommendations and coverage rates in the EU Member States for the 2012-13 influenza season. Stockholm: ECDC; Jan 2015. Available from: http://ecdc.europa.eu/en/publications/Publications/Seasonal-influenza-vaccination-Europe-2012-13.pdf
  17. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season. Geneva: WHO; Feb 2015. Available from: http://www.who.int/entity/influenza/vaccines/virus/recommendations/2015_16_north/en/index.html
  18. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation. Summary Europe. Stockholm: ECDC; Jun 2016. Available from: http://ecdc.europa.eu/en/publications/Publications/influenza-virus-characterisation-june-2016.pdf
  19. EpiConcept. Protocol for hospital-based test negative case control studies to measure seasonal influenza vaccine effectiveness against influenza laboratory confirmed SARI hospitalisation among the elderly across the European Union and European Economic Area Member States. Paris: Integrated Monitoring of Vaccines in Europe plus (I-MOVE+). [Accessed 4 May 2016]. Available from: https://drive.google.com/a/epiconcept.fr/file/d/0B54XpZN4SY65QXFqQThQNEQ5cmM/view
  20. EpiConcept. I-MOVE+ (Integrated Monitoring of Vaccines in Europe plus). Paris: I-MOVE+. [Accessed 5 Jul 2017]. http://www.i-moveplus.eu/wp2
  21. VENICE II Consortium. Seasonal influenza vaccination survey in EU/EEA, influenza season 2009-10. Final report. Rome: VENICE project; 2011 [Accessed 24 Oct 2013]. Available from: http://venice.cineca.org/Final_Seasonal_Influenza_Vaccination_Survey_2010.pdf
  22. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med J. 1965;14:61-5. PMID: 14258950 
  23. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193-206.  https://doi.org/10.1037/1082-989X.11.2.193  PMID: 16784338 
  24. Rondy M, Launay O, Puig-Barberà J, Gefenaite G, Castilla J, de Gaetano Donati K, et al. 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals. Euro Surveill. 2015;20(2):21011.  https://doi.org/10.2807/1560-7917.ES2015.20.2.21011  PMID: 25613779 
  25. Rondy M, Castilla J, Launay O, Costanzo S, Ezpeleta C, Galtier F, et al. Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network. Hum Vaccin Immunother. 2016;12(5):1217-24.  https://doi.org/10.1080/21645515.2015.1126013  PMID: 27065000 
  26. Broberg E, Melidou A, Prosenc K, Bragstad K, Hungnes O. Predominance of influenza A(H1N1)pdm09 virus genetic subclade 6B.1 and influenza B/Victoria lineage viruses at the start of the 2015/16 influenza season in Europe. Euro Surveill. 2016;21(13):30184.  https://doi.org/10.2807/1560-7917.ES.2016.21.13.30184  PMID: 27074657 
  27. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation Summary Europe. Stockholm: ECDC; Jul 2013. Available from: http://ecdc.europa.eu/en/publications/Publications/influenza-virus-characterisation-July-2013.pdf
  28. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9(3):e92153.  https://doi.org/10.1371/journal.pone.0092153  PMID: 24667168 
  29. Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter A-L, Gubbay JB, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis. 2014;210(1):126-37.  https://doi.org/10.1093/infdis/jiu048  PMID: 24446529 
  30. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11(1):153.  https://doi.org/10.1186/1741-7015-11-153  PMID: 23800265 
  31. Talbot HK, Nian H, Zhu Y, Chen Q, Williams JV, Griffin MR. Clinical effectiveness of split-virion versus subunit trivalent influenza vaccines in older adults. Clin Infect Dis. 2015;60(8):1170-5.  https://doi.org/10.1093/cid/civ019  PMID: 25697739 
  32. Castilla J, Navascués A, Fernández-Alonso M, Reina G, Pozo F, Casado I, et al. . Effectiveness of subunit influenza vaccination in the 2014-2015 season and residual effect of split vaccination in previous seasons. Vaccine. 2016;34(11):1350-7.  https://doi.org/10.1016/j.vaccine.2016.01.054  PMID: 26854911 
  33. Puig-Barberà J, García-de-Lomas J, Díez-Domingo J, Arnedo-Pena A, Ruiz-García M, Limón-Ramírez R, et al. Influenza vaccine effectiveness in preventing influenza A(H3N2)-related hospitalizations in adults targeted for vaccination by type of vaccine: a hospital-based test-negative study, 2011-2012 A(H3N2) predominant influenza season, Valencia, Spain. PLoS One. 2014;9(11):e112294.  https://doi.org/10.1371/journal.pone.0112294  PMID: 25392931 
  34. Co MDT, Orphin L, Cruz J, Pazoles P, Green KM, Potts J, et al. In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine. 2009;27(2):319-27.  https://doi.org/10.1016/j.vaccine.2008.09.092  PMID: 18977404 
  35. Atmar RL, Keitel WA. Influenza Vaccination of Patients Receiving Statins: Where Do We Go From Here? J Infect Dis. 2016;213(8):1211-3.  https://doi.org/10.1093/infdis/jiv459  PMID: 26516140 
  36. Black S, Nicolay U, Del Giudice G, Rappuoli R. Influence of Statins on Influenza Vaccine Response in Elderly Individuals. J Infect Dis. 2016;213(8):1224-8.  https://doi.org/10.1093/infdis/jiv456  PMID: 26516142 
  37. Choi DK, Fuleihan RL, Walterhouse DO. Serologic response and clinical efficacy of influenza vaccination in children and young adults on chemotherapy for cancer. Pediatr Blood Cancer. 2016;63(11):2011-8.  https://doi.org/10.1002/pbc.26110  PMID: 27327360 
  38. Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008;8(1):79.  https://doi.org/10.1186/1471-2288-8-79  PMID: 19036172 
  39. Skowronski DM, Chambers C, Sabaiduc S, Janjua NZ, Li G, Petric M, et al. Pre- and postpandemic estimates of 2009 pandemic influenza A(H1N1) seroprotection to inform surveillance-based incidence, by age, during the 2013-2014 epidemic in Canada. J Infect Dis. 2015;211(1):109-14.  https://doi.org/10.1093/infdis/jiu366  PMID: 24973459 
  40. Foppa IM, Ferdinands JM, Chaves SS, Haber MJ, Reynolds SB, Flannery B, et al. The case test-negative design for studies of the effectiveness of influenza vaccine in inpatient settings. Int J Epidemiol. 2016;dyw022.  https://doi.org/10.1093/ije/dyw022  PMID: 26979985 
  41. Castilla J, Martínez-Artola V, Salcedo E, Martínez-Baz I, Cenoz MG, Guevara M, et al. Vaccine effectiveness in preventing influenza hospitalizations in Navarre, Spain, 2010-2011: cohort and case-control study. Vaccine. 2012;30(2):195-200.  https://doi.org/10.1016/j.vaccine.2011.11.024  PMID: 22100636 
  42. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter A-L, Dickinson JA, et al. A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season. Clin Infect Dis. 2016;63(1):21-32.  https://doi.org/10.1093/cid/ciw176  PMID: 27025838 
  43. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci USA. 1999;96(24):14001-6.  https://doi.org/10.1073/pnas.96.24.14001  PMID: 10570188 
  44. McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL, Friedrich TC, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis. 2014;59(10):1375-85.  https://doi.org/10.1093/cid/ciu680  PMID: 25270645 
/content/10.2807/1560-7917.ES.2017.22.30.30580
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error